Eli Lilly has developed artificial intelligence models that can help predict the behavior of potential drug candidates, based on the data the drugmaker has collected over the last two decades and at the cost of more than a billion dollars. Now, it’s opening up some of those models to biotech companies that want to use them to jumpstart their science.

The only catch? Lilly wants to use data from those other companies to improve its models.

The models will be offered on a new platform called Lilly TuneLab and will initially include 18 models, 12 aimed at predicting small-molecule drug properties and six for assessing whether antibodies are amenable to further development. More will come in the future, including a model from drug development AI unicorn Insitro focused on analyzing data pr

See Full Page